Kidney cytosine methylation changes improve renal function decline estimation in patients with diabetic kidney disease

被引:0
|
作者
Caroline Gluck
Chengxiang Qiu
Sang Youb Han
Matthew Palmer
Jihwan Park
Yi-An Ko
Yuting Guan
Xin Sheng
Robert L. Hanson
Jing Huang
Yong Chen
Ae Seo Deok Park
Maria Concepcion Izquierdo
Ioannis Mantzaris
Amit Verma
James Pullman
Hongzhe Li
Katalin Susztak
机构
[1] University of Pennsylvania,Department of Medicine, Renal Electrolyte and Hypertension Division
[2] University of Pennsylvania,Department of Pediatrics, Division of Nephrology, The Children’s Hospital of Philadelphia, Perelman School of Medicine
[3] Inje University College of Medicine,Division of Nephrology, Department of Internal Medicine
[4] University of Pennsylvania,Department of Pathology and Laboratory Medicine, Perelman School of Medicine
[5] University of Pennsylvania,Department of Genetics
[6] Diabetes Epidemiology and Clinical Research Section,Department of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, School of Medicine
[7] National Institute of Diabetes and Digestive and Kidney Diseases,Department of Medicine
[8] University of Pennsylvania Perelman,undefined
[9] Albert Einstein College of Medicine,undefined
[10] Department of Pathology Montefiore Medical Center,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Epigenetic changes might provide the biological explanation for the long-lasting impact of metabolic alterations of diabetic kidney disease development. Here we examined cytosine methylation of human kidney tubules using Illumina Infinium 450 K arrays from 91 subjects with and without diabetes and varying degrees of kidney disease using a cross-sectional design. We identify cytosine methylation changes associated with kidney structural damage and build a model for kidney function decline. We find that the methylation levels of 65 probes are associated with the degree of kidney fibrosis at genome wide significance. In total 471 probes improve the model for kidney function decline. Methylation probes associated with kidney damage and functional decline enrich on kidney regulatory regions and associate with gene expression changes, including epidermal growth factor (EGF). Altogether, our work shows that kidney methylation differences can be detected in patients with diabetic kidney disease and improve kidney function decline models indicating that they are potentially functionally important.
引用
收藏
相关论文
共 50 条
  • [31] Renal Function following Fluorescein Angiography in Diabetic Patients with Chronic Kidney Disease
    Ebrahimiadib, Nazanin
    Mirzaei, Shaghayegh Hadavand
    Riazi-Esfahani, Hamid
    Amini, Manouchehr
    JOURNAL OF OPHTHALMIC & VISION RESEARCH, 2023, 18 (02) : 170 - 174
  • [32] Alterations of Renal Function in Patients with Diabetic Kidney Disease: A BOLD and DTI Study
    Wei, Xiaobao
    Hu, Runyue
    Zhou, Xiaoli
    Ni, Lihua
    Zha, Dongqing
    Feng, Huiling
    Xu, Haibo
    Wu, Xiaoyan
    COMPUTATIONAL INTELLIGENCE AND NEUROSCIENCE, 2022, 2022
  • [33] Direct-acting antivirals improve kidney function in diabetic patients with HCV infection and chronic kidney disease
    Rosanna Villani
    Antonino Davide Romano
    Moris Sangineto
    Gaetano Serviddio
    Internal and Emergency Medicine, 2021, 16 : 1239 - 1245
  • [34] Direct-acting antivirals improve kidney function in diabetic patients with HCV infection and chronic kidney disease
    Villani, Rosanna
    Romano, Antonino Davide
    Sangineto, Moris
    Serviddio, Gaetano
    INTERNAL AND EMERGENCY MEDICINE, 2021, 16 (05) : 1239 - 1245
  • [35] Rapid decline of kidney function in diabetic kidney disease is associated with high soluble Klotho levels
    Bob, Flaviu
    Schiller, Adalbert
    Timar, Romulus
    Lighezan, Daniel
    Schiller, Oana
    Timar, Bogdan
    Bujor, Cristiana Georgeta
    Munteanu, Mircea
    Gadalean, Florica
    Mihaescu, Adelina
    Grosu, Iulia
    Hategan, Andreea
    Chisavu, Lazar
    Pusztai, Agneta-Maria
    Covic, Adrian
    NEFROLOGIA, 2019, 39 (03): : 250 - 257
  • [36] Lead chelation therapy retards the decline of renal function in patients with chronic kidney disease
    Vecihi Batuman
    Nature Clinical Practice Nephrology, 2007, 3 : 646 - 647
  • [37] CARDIOVASCULAR EVENTS DO NOT ACCELERATE DECLINE OF RENAL FUNCTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE
    Jeyaruban, A.
    Hoy, W. E.
    Cameron, A.
    Healy, H. G.
    Zhang, J.
    Mallett, A. J.
    NEPHROLOGY, 2018, 23 : 44 - 44
  • [38] Lead chelation therapy retards the decline of renal function in patients with chronic kidney disease
    Batuman, Vecihi
    NATURE CLINICAL PRACTICE NEPHROLOGY, 2007, 3 (12): : 646 - 647
  • [39] Slowing renal function decline in chronic kidney disease patients after nephrology referral
    Chen, Szu-Chia
    Chang, Jer-Ming
    Chou, Ming-Chin
    Lin, Ming-Yen
    Chen, Jui-Hsin
    Sun, Jia-Hui
    Guh, Jinn-Yuh
    Hwang, Shang-Jyh
    Chen, Hung-Chun
    NEPHROLOGY, 2008, 13 (08) : 730 - 736
  • [40] 12(S)-hydroxyeicosatetraenoic acid is significantly increased in diabetic kidney disease and associated with renal function decline
    Xu, Jie
    Jin, Li
    Sun, Yi
    Zhang, Rong
    Chen, Xianghui
    Zhou, Ranran
    Gu, Yunjuan
    Hu, Cheng
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2022, 38 (06)